Effects of the COVID-19 pandemic on people experiencing incarceration: a systematic review.

Objective: To assess the effect of the COVID-19 pandemic on people experiencing incarceration (PEI), focusing particularly on clinical outcomes compared with the general population.

Design: Systematic review with narrative synthesis in accordance with the Centre for Reviews and Dissemination's good practice guidelines.

Data Sources: Medline, Social Policy and Practice, Criminology Connection, ASSIA, EMBASE, SCOPUS, Web Of Science, CINAHL, Cochrane Library, Cochrane COVID-19 reviews, COVID-19 Evidence Reviews and L*OVE COVID-19 Evidence databases were searched up to 21 October 2022.

Mitigating COVID-19 Burden in People Experiencing Incarceration: A Systematic Review.

People experiencing incarceration (PEI) have poorer COVID-19 clinical outcomes compared with the general population. Many interventions were implemented in incarceration facilities to mitigate the burden of COVID-19. This systematic review seeks to analyze the effectiveness of these interventions.

Interventions to mitigate the risks of COVID-19 for people experiencing homelessness and their effectiveness: a systematic review.

Objectives: People experiencing homelessness also experience poorer clinical outcomes of COVID-19. Various interventions were implemented for people experiencing homelessness in 2020-2022 in different countries in response to varied national guidance to limit the impact of COVID-19. It is important to understand what was done and the effectiveness of such interventions.

The Impact of Being Homeless on the Clinical Outcomes of COVID-19: Systematic Review.

The homeless population experiences inequality in health compared with the general population, which may have widened during the COVID-19 pandemic. However, the impact of being homeless on the outcomes of COVID-19 is uncertain. This systematic review aimed to analyse the impact of experiencing homelessness on the clinical outcomes of COVID-19, including the effects on health inequalities.

A double blind clinical study comparing the safety, tolerance and efficacy of ioversol 240 and iohexol 240 (Omnipaque 240) in ascending venography.

A randomised, double blind, parallel group study was performed comparing the efficacy, tolerance and safety of ioversol-240 and iohexol-240 (Omnipaque-240) in 50 patients undergoing venography. Adult patients of either sex, 18 years of age or older, who were referred to the Department of Radiology at Northwick Park Hospital, Harrow, England, for ascending venography were study candidates. There were 25 patients in each drug group, who were comparable in relation to age, sex, weight, height and race.